In a groundbreaking study, two teams of researchers — one based at the University of South Australia in Adelaide and another in London — have shown that stroke recovery peaks at approximately two weeks after the stroke and then gradually diminishes with the passage of time.
The teams at Adelaide and London followed a total of 60 patients who had had a stroke. This follow-up lasted up to 12 months after the stroke.
Dr. Brenton Hordacre, based at the University of South Australia in Adelaide and also the lead author of the study, explained that this multisite study was intended to find out whether what was observed in animal studies could also be witnessed in human stroke survivors.
The team conducted scans on the brains of the victims using continuous transcranial brain stimulation (“cTBS”) to repeatedly activate different hemispheres of the victims’ motor cortex. The intention was to track brain plasticity in the victims. The laboratory in Adelaide focused on measuring plasticity within the damaged hemisphere of the motor cortex while the laboratory in London focused on the intact hemisphere of the motor cortex. This intact side is vital because it plays an important role in the recovery of the patient. Their assessments revealed that brain plasticity was at its highest 14 days post-stroke within the cortex that didn’t suffer any damage.
The lead author asserts that their findings confirm how important it is to initiate therapy immediately after someone has suffered a stroke.
The latest evidence shows that at the moment, a maximum of eight minutes is devoted each day to helping stroke victims recover function in their upper limbs in the first four weeks after a stroke. The research team believes that the treatment outcomes can be improved if more time is devoted to therapy within this window, as the chance of recovery decreases as time passes after the two-week mark.
Hordacre says more study and research needs to be done, despite the groundbreaking findings that they obtained in their study, which was published early this month. For example, he points out that attention needs to be directed towards identifying the specific therapy techniques that have the capacity to extend or even reopen the period when brain plasticity remains high after one has had a stroke. Such techniques have the potential to make full recovery a possibility, even in people who have suffered a severe stroke.
Many companies are currently investing significant resources in identifying conditions that affect the brain, such as Brain Scientific Inc. (OTCQB: BRSF). With a mission of modernizing brain diagnostics, Brain Scientific develops innovative and proprietary medical devices and software.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Approximately 20% of people in the U.S. live in a rural area, and they face…
On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant…
Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer.…
Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been…
Many existing cancer treatments, such as chemotherapy and radiation, don’t distinguish between cancer cells and…
A study whose findings were recently published has provided insights into the cost of treating…